1. The Changing Therapeutic Landscape of CINV

2. Program Goals

3. Preventing CINV: Why Do We Need New Agents?

4. Emetogenicity of Chemotherapy

5. Antiemetic Guidelines Current Recommendations for Patients Receiving HEC

6. Antiemetic Guidelines Current Recommendations for Patients Receiving MEC

7. Preventing CINV: Why Do We Need New Agents? (cont)

8. Evidence That Guideline-based Care Is Effective in the Prevention of CINV

9. New Antiemetic Agents and Formulations

10. Aprepitant: Drug-Drug Interactions

11. Rolapitant: Drug-Drug Interactions

12. Rolapitant in Patients Receiving MEC Phase 3 Study Design

13. Rolapitant in Patients Receiving MEC Efficacy Results

14. Rolapitant in Patients Receiving MEC Safety

15. NEPA + DEX vs Oral PALO + DEX in AC-based MEC Multinational, Randomized, Double-blind Phase 3 Study

16. NEPA + DEX vs PALO + DEX in AC-based MEC CR Rates (cycle 1)

17. NEPA + DEX vs Oral PALO + DEX in AC-based MEC Overall CR Rates Across Multiple Cycles

18. NEPA + DEX vs PALO + DEX in AC-Based MEC Safety Across Multiple Cycles

19. NEPA + DEX vs PALO + DEX in AC-based MEC Most Common TRAEs Across Multiple Cycles

20. The Problem of Nausea

21. Summary

22. Abbreviations

23. Abbreviations (cont)

24. References

25. References (cont)

26. References (cont)

27. References (cont)

28. References (cont)

29. References (cont)

30. References (cont)